Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 20, No. 2, 1997
Issue release date: 1997
Section title: Original Article
Onkologie 1997;20:126–131
(DOI:10.1159/000218912)

Prognostic Factors for Survival in Inoperable Non-Small-Cell Lung Cancer: A Multivariate Regression Analysis of 456 Patients with Radiation Therapy

Ohlhauser C.a · Bülzebruck H.a · Ebert W.a · Drings P.a · Wannenmacher M.b
aThoraxklinik Heidelberg-Rohrbach der LVA Baden, Heidelberg bUniversitäts-Strahlenklinik Heidelberg

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Published online: May 12, 2009
Issue release date: 1997

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: http://www.karger.com/ORT

Abstract

Background: The aim of the present analysis was to evaluate the dominating independent prognostic factors of patients with non-small-cell lung cancer (NSCLC) and radiation therapy. Based on these factors, a prognostic index for survival was created and used to divide the patient population into different prognostic groups. Patients and Methods: Prognostic factors for survival were prospectively evaluated between January 1, 1987 and December 31, 1990 at the Thoraxklinik Heidelberg-Rohrbach in 456 previously untreated patients with advanced NSCLC who had received radiation therapy. Data on 30 pretreatment variables were investigated including 5 tumor-associated, 5 host-associated and 20 initial laboratory parameters. Results: Univariate analysis demonstrated that 16 of these variables were favorable prognostic factors for survival. The subsequent multivariate analysis using Cox’s proportional hazard model revealed that a hemoglobin level greater than 12.7 g/dl (p = 0.006), a lactate dehydrogenase less than or equal to 200 U/l (p = 0.035), a serum gamma-glutamyl transpeptidase (GGT) less than or equal to 60 U/l (p = 0.032), a lymphocyte count greater than 2.0/nl (p = 0.008), and a low stage of disease (TNM stages I + II) (p < 0.001) contributed independently to survival. On the basis of these 5 independent prognostic factors, a prognostic index for survival of each patient was calculated to define 3 prognostic groupings (good, intermediate, poor). The median survival within these groups was 412 days vs. 260 days vs. 133 days (p = 0.001). Conclusions: By using prognostic factors for treatment evaluation, a better individual judgement of patients could be obtained and the treatment regimes within the prognostic different subgroups could be improved. The prognostic index could be used to identify more precisely, those patients, who profit from an aggressive therapy, in order to save patients with bad prognosis from invasive treatment that could impair their quality of life and shorten their survival time.

© 1997 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Article

Published online: May 12, 2009
Issue release date: 1997

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: http://www.karger.com/ORT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.